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Objectives Renal disease is increasingly regarded as an independent risk factor for vascular disease which in itself is
believed to influence risk of AD. Alterations in amyloid homeostasis via reduced renal clearance of peripheral beta-amyloid
(Aj*beta*j) may represent another potential role for variation in renal function leading to increased risk of AD. We sought to
examine estimates of glomerular filtration rate in AD and control groups.
Methods AD patients were randomly recruited from the Memory Clinic of the Belfast City Hospital (n¼ 83). Genomic
DNA was extracted from peripheral leucocytes and was genotyped for Apolipoprotein E using standard methods. Using
creatinine values, age and gender, estimated Glomerular Filtration Rates (eGFR) were calculated using the isotope dilution
mass spectrometry (IDMS)-traceable Modification of Diet in Renal Disease (MDRD) Study equation (using the United
Kingdom National External Quality Assessment Scheme (UKNEQAS) correction factor). IDMS eGFR values were then
compared between AD and control groups.
Results Significant baseline differences in age, diastolic blood pressure, education level attained and APOE j*epsilon*j4
carriage were noted between cases and controls. The AD group had a significantly lower eGFR versus controls (69 vs 77 ml/
min) which persisted after adjustment for possible confounders (p¼ 0.045).
Conclusions This case-control analysis suggests that using a relatively accurate estimate of renal function, patients withAD have
greater renal impairment than cognitively normal controls. This may reflect impaired renal clearance of peripheral Aj*beta*j or be a
marker of shared vascular processes altering cerebral and renal functioning. Copyright # 2009 John Wiley & Sons, Ltd.key words—Alzheimer’s disease; amyloid; dementia; renal disease; glomerular filtration rateINTRODUCTION
Alzheimer’s disease (AD) is the most common form of
dementia with a prevalence of 24–33% in those aged
over 85 (Ferri et al., 2005). It is a progressive neuro-
degenerative condition leading to enormous personal
and health economic burden.
Development of AD is associated with several
different genetic and environmental factors. Genetic
mutations in amyloid precursor protein (APP) on*Correspondence to: D. Craig, Department of Geriatric Medicine,
Queen’s University of Belfast, 97 Lisburn Road, Belfast BT9 7BL,
UK. E-mail: david.craig@qub.ac.uk
Copyright # 2009 John Wiley & Sons, Ltd.chromosomes 21, presenilin 1 (chromosome 14) and
presenilin 2 (chromosome 1) cause autosomal
dominant familial AD (Goate et al., 1991; Levy-
Lahad et al., 1995; Sherrington et al., 1995). The e4
allele of the APOE gene is a genetic risk factor for
sporadic late onset AD (Corder et al., 1993; Farrer
et al., 1997). Age, along with female gender, lower
educational attainment and a history of head injury are
additional risk factors for sporadic AD (Andersen
et al., 1999; Ferri et al., 2005; McDowell et al., 2007).
A number of epidemiological studies have acknowl-
edged a role for vascular risk factors in AD (Mayeux,
2003). Prospective cohort studies have identified
smoking, hypertension, atrial fibrillation, diabetes,Received 24 June 2008
Accepted 13 November 2008
928 e. kerr ET AL.hypercholesterolaemia, APOE e4 polymorphism,
elevated CRP, low folate levels, hyperhomocystei-
naemia, obesity, and arterial stiffness as potential risk
factors for the development of AD (Farrer et al., 1997;
Kivipelto et al., 2001; Seshadri et al., 2002; Gustafson
et al., 2003; Hofman et al., 2007). The Rotterdam
Study (Hofman et al., 1997) evaluated 284 patients
with dementia, 207 of whom had AD, and 1698 non-
demented controls. The study found that indicators of
atherosclerosis (vessel wall thickness, plaques of the
carotid arteries and ratio of ankle-to-brachial systolic
blood pressure) were associated with dementia and its
major subtypes: AD (Odds Ratio (OR) 1.3–1.8) and
Vascular Dementia (VaD) (OR 1.9–3.2). The frequen-
cies of all dementia, AD and VaD increased with the
degree of atherosclerosis. The OR for AD in those
with severe atherosclerosis compared to those without
atherosclerosis was 3.0 (95% Confidence Intervals
(CI) 1.5–6.0; p¼ 0.001). However, there has been
limited and at times conflicting evidence when
interventional studies targeted at key cardiovascular
risk factors such as cholesterol or hypertension are
examined in established and at-risk populations
(Bifulco et al., 2008; McGuinness et al., 2008).
Acknowledging the established link between
impaired renal function and vascular disease in
general (as well as stroke and carotid atherosclerosis
in particular) (Lass et al., 1999; Savazzi et al., 2001;
Seliger et al., 2004), previous studies have focused
predominantly on the increased risk of VaD associated
with reduction in GFR or overt renal failure.
Longitudinal and cross-sectional studies have shown
that chronic kidney disease with moderate reductions
in GFR is associated with an increased risk of
dementia among older adults (Seliger et al., 2004).
The Cardiovascular Health Cognition Study followed
3349 subjects and found 477 cases of incident
dementia over a median 6 years (211 VaD and 244
AD). They found an elevated baseline serum
creatinine (SCr) (expressed as 1/SCr) to be associated
with a 58% increased risk of VaD but found no
significant association with AD. Few case-control
studies have previously examined differences in renal
function between dementia groups and controls
although we have reported a prior difference in serum
creatinine levels between vascular, AD and normal
subjects (McIlroy et al., 2002). To the best of our
knowledge, no clinical trial evidence is available to
show that therapeutic intervention in renal disease
lessens the risk of subsequent cognitive impairment.
The chief component of senile plaques, Ab pep-
tides, likely play a central role in the pathological
processes underlying AD (Hardy and Selkoe, 2002).Copyright # 2009 John Wiley & Sons, Ltd.Evidence suggests that Ab deposition and plaque
formation is a dynamic process involving a fine
balance of Ab production and clearance from the brain
(Zlokovic et al., 2000; Selkoe 2001; Ghiso et al.,
2004; Bates et al., 2008). Normal cerebral Ab
concentrations are maintained by numerous pathways
including receptor for advanced end glycation
products (RAGE) mediated influx and low-density
lipoprotein receptor related protein 1 (LRP) mediated
clearance across the blood brain barrier (BBB) (Deane
et al., 2004). Increasingly, it has been recognised that
peripheral production of Ab outside the brain may
play a part in this process (DeMattos et al., 2001; Tang
et al., 2006; Johnston et al., 2008). Increased
peripheral production could reduce the capacity for
clearance of cerebral Ab across the BBB triggering the
sequence of events culminating in cognitive deficits.
Regulation of Ab levels is also dependent on
cerebral and systemic Ab catabolism and elimination.
Multiple proteases which degrade Ab have been
identified (Iwata et al., 2001; Selkoe, 2001; Zlokovic
et al., 2005; Nalivaeva et al., 2008). The liver is a
known contributor to plasma clearance of Ab (>60%)
(Ghiso et al., 2004). Renal clearance has also been
identified as another elimination pathway with rat
studies showing high urinary levels of radioactive
tracer after infusion of radio labelled Ab into the
lateral ventricles (Ghersi-Egea et al., 1996). In human
subjects, a positive correlation has been identified
between serum creatinine and plasma Ab concen-
trations (Arvanitakis et al., 2002). In addition, a recent
study showed that haemodialysis effectively reduced
plasma Ab by 30% from baseline in patients with
chronic renal failure (Rubio et al., 2006). Ab
immunotherapy promotes clearance of Ab from the
brain, resulting in increased plasma Ab and reduced
cortical amyloid load (Lemere et al., 2004). If
peripheral clearance of Ab is reduced, this ‘peripheral
sink’ capacity would be compromised and cortical
amyloid levels would be predicted to increase.
The role of impaired renal function in AD remains a
relatively unexplored area. Renal disease is increas-
ingly regarded as an independent risk factor for
cerebrovascular and cardiovascular disease via pro-
posed mechanisms involving inflammatory mediation,
activation of the renin-angiotensin system, enhanced
production of reactive oxygen species and endothelial
dysfunction, promotion of vascular calcification,
hypertension and dyslipidaemia (Schiffrin et al.,
2007). This process, perhaps in conjunction with
the alterations in amyloid homeostasis outlined above,
may indicate a potential role for changes in renal
function to increase risk of AD. We have thereforeInt J Geriatr Psychiatry 2009; 24: 927–932.
DOI: 10.1002/gps
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of renal function, namely eGFR (as measured by the
IDMS-MDRD eGFR equation), and AD, using a case
control design in the context of examining measures of
known vascular risk.
METHODS
Ethical approval for this study was obtained from the
Research Ethics Committee, Queen’s University
Belfast. Written informed consent was obtained from
patients, caregivers and controls. All subjects with a
strong family history of dementia (1 first degree
relative) were excluded. All patients and controls were
Caucasian.
Patients were randomly recruited from the Memory
Clinic of the Belfast City Hospital (n¼ 83). Controls
were recruited from non-demented healthy spouses
and volunteers from the local podiatry clinic or
retirement clubs throughout Northern Ireland (n¼ 71).
The diagnosis of probable AD was determined by
two experienced clinicians using the National Institute
of Neurological and Communicative Diseases and
Stroke/Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) criteria (McKhann
et al., 1984). A computerised tomography scan was
performed to aid diagnosis in the majority of cases.
Cognitive function was assessed using Mini Mental
State Examination (MMSE) (Folstein et al., 1975).
Controls subjects with a MMSE 28 were included.
All subjects and controls had age, gender, blood
pressure, smoking status and level of educational
attainment recorded. Fasting blood samples were
reserved for measurement of serum cholesterol and
serum creatinine. Genomic DNA was extracted from
peripheral leucocytes by the salting out method and
was genotyped for APOE using standard methods
(Hixson and Vernier, 1990). Using creatinine values,
age and gender, eGFRs were calculated using the
IDMS traceable MDRD equation (Levey et al., 1999;
Vickery et al., 2006) (employing the UKNEQAS
correction factor) as shown:IDM traceable equation
GFR ¼ 175
 ½ðfserum creatinine interceptg=slopeÞ
 0:0113121:154  age0:203
 ð0:742 if femaleÞCopyright # 2009 John Wiley & Sons, Ltd.;GFR ¼ 175
 ½ðfserum creatinine 7:71g=0:988Þ
 0:0113121:154  age0:203
 ð0:742 if femaleÞ
A factor for race is excluded as all subjects were
Caucasian.
IDMS eGFR values were then compared between
AD and control groups (C).
STATISTICAL ANALYSIS
Student’s t-test was used to compare normally
distributed eGFR values in AD and control groups.
Multiple regression analysis was used to adjust for
potential confounding factors. Normally distributed
confounding variables were analysed using Student’s
t-test. The level of statistical significance was set at
p¼ 0.05. All analyses were performed using the
SPSS statistical software package (version 14.0
Chicago, IL).
RESULTS
Comparison of the control and patient groups is
presented along with demographic and baseline data
in Table 1. Control subjects were younger and more
commonly female. Although there were no differences
in systolic blood pressure, controls had a higher
diastolic blood pressure. There was no difference in
cholesterol levels. There were no significant differ-
ences in smoking status between AD and control
subjects. The proportion of subjects attending
secondary level education or higher was significantly
lower in the AD group. As expected, APOE e4 allele
carriage was more prevalent in the AD group. The AD
group had significantly higher creatinine levels.
Differences in IDMSeGFR between groups was
significantly lower in AD subjects (p¼ 0.002; 69.0 vs
76.9ml/min).
After adjustment for the potential confounders (age,
diastolic, APOE e4 and education level) identified
during baseline comparison, (Table 2) a significantly
lower eGFR remained in the AD group compared to
controls (p¼ 0.045).
DISCUSSION
Our cross-sectional study shows an association
between impaired renal function as measured by
IDMSeGFR and AD. Our report is the first to useInt J Geriatr Psychiatry 2009; 24: 927–932.
DOI: 10.1002/gps
Table 1. Subject characteristics
AD Control
N 83 71
Age mean{SD}/yr 77.2 {8.1} 74.3 {7.6} p¼ 0.023
Gender
% male 30.1% 19.7% NS
% female 69.9% 80.3% (p¼ 0.097)
Positive carriage of APOE e4 43.8% 18.3% p¼ 0.001
Systolic BP mean{SD}/mmHg 144 {23} 148 {14} NS
Diastolic BP mean{SD}/mmHg 79 {12} 83 {9} p¼ 0.017
Smoking Status
Never 64.2% 69.6%
Ex-smoker 21.0% 17.4% NS
Current 14.8% 13.0%
Cholesterol mean{SD}/mmol/l 5.5 {1.8} 5.5 {1.9} NS
MMSE median {IQR} 18.4 {14–22} 28 N/A
Education level p¼ 0.001
% secondaryþ above 26.3% 52.9%
Creatinine mean{SD}/mmol/l 87.4 {18.0} 77.9 {12.1} p< 0.001
IDMSeGFR Mean{SD}/ ml/min 69.0 {14.6} 76.9 {16.3} p¼ 0.002
930 e. kerr ET AL.corrected glomerular filtration rate equations as a
measure of renal function and thus has the advantage
of greater accuracy over previous measures dependent
on serum creatinine (Swedko et al., 2003). The
MDRD and the IDMS equations are now accepted as
the gold standard measurements of eGFR (Levey
et al., 1999; Vickery et al., 2006). There are no known
studies using these techniques in AD and the increased
sensitivity of these measures of renal impairment may
explain our findings and which require confirmation.
After vascular influences were examined, statistical
significance was retained. One weakness of our report
is that not all key cardiovascular risk factors were
available for analysis; additional vascular factors may
account for the observed differences. Another is the
lack of drug-use data in our dataset.
Alterations in amyloid homeostasis and in the
peripheral sink capacity may represent an independent
pathogenic mechanism. Ghiso and co-workers, exam-
ining the excretion and catabolism of circulating
peripheral Ab in mice, found labelled substrate mostly
cleared by liver (>60%), followed by the kidneyTable 2. The Difference in estimated glomerular filtration rate in A
Dif
Unadjusted 7
Adjusted for Age
Adjusted for APOE
Adjusted for Diastolic BP
Adjusted for Education level
Adjusted for Age, APOE, Diastolic BP,þEducation level
Copyright # 2009 John Wiley & Sons, Ltd.(Ghiso et al., 2004). We note the recent report by
Arvanitakis et al. (2002) showing a positive corre-
lation between serum creatinine and plasma Ab levels
in both normal individuals and subjects with AD. The
implications are therefore two-fold: that renal
impairment slows or prevents the passage of amyloid
from brain to periphery where it is subject to
excretion, or alternatively, that amyloid excess is
somehow limiting to normal renal function in a
subclinical context and is thus the upstream event.
The result should be seen in the context of issues
relating to apparently overlapping pathogenic mech-
anisms involving cerebrovascular and Ab plaque
pathology in AD as well as the clinical and
neuropathological distinction between VaD and AD.
The neurovascular hypothesis of AD suggests that
dysfunctional blood vessels could contribute to
cognitive dysfunction by impairing delivery of
nutrients to neurons and by reducing Ab clearance
from the brain (Iadecola, 2004). Other researchers
argue that vascular pathology in AD occurs indepen-
dently and synergistically acts to expose cognitivelzheimer’s dementia compared to control
ference in eGFR 95% CI p-value N
.95 12.9 to 3.0 0.002 151
0.006
0.001
0.005
0.012
0.045
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of pathology (Riekse et al., 2004; Blennow et al.,
2006). It is believed that VaD and AD represent
opposite ends of an overlapping continuum and this
can lead to difficulties in definitively classifying
patients with dementia into distinct groups and will
necessarily produce uncertainties in interpreting
studies involving vascular risk factors.
Cognitive decline, cardiovascular ill-health and
renal impairment may arise from shared vascular and/
or inflammatory mechanisms. Candidate genes such as
apolipoprotein E (APOE) exist as an established
susceptibility factor for AD and have been linked to
cardiovascular disease: knockout of the APOE gene in
mice causes hypercholesterolemia and early athero-
sclerosis (Plump et al., 1992). Similarly, angiotensin-
converting enzyme (ACE) which is expressed in
vascular endothelial tissue and renal epithelial cells is
of possible relevance to end organ damage in brain and
kidneys as evidenced by some, but not all, genetic
susceptibility studies (Betram et al., 2007; Jeunemai-
tre, 2008). Shared putative genetic correlates invol-
ving inflammatory pathways are in the same way
advocated in AD and CKD (Rao et al., 2007; Skaper,
2007). In these areas, the possibility exists that
preventative or slowing strategies developed in the
context of one disorder may have crossover benefit in
another.
This cross-sectional study is consistent with the
hypothesis that lowered eGFR acts as risk factor for
AD. As these associations are not necessarily causa-
tive they do highlight the need for confirmatory work
as well as prospective studies and intervention trials.
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